New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options introduced in recent years have resulted in improved survival outcomes, multiple myeloma remains incurable for a large number of patients, and new treatment options are urgently needed. Over the last 5 years, there has been a renewed interest in the clinical potential of immunotherapy for the treatment of multiple myeloma. Clinical progression of myeloma is known to be associated with progressive immune dysregulation and loss of immune surveillance that contribute to disease progression in association with progressive genetic complexity, rendering signaling-based treatments less effective. A variety of strategies to reverse the multiple myeloma–induced immunosuppression has been developed either in the form of immunomodulatory drugs, checkpoint inhibitors, mAbs, engineered T cells, and vaccines. They have shown encouraging results in patients with relapsed refractory multiple myeloma and hold great promise in further improving patient outcomes in multiple myeloma. This review will summarize the major approaches in multiple myeloma immunotherapies and discuss the mechanisms of action and clinical activity of these strategies. Clin Cancer Res; 22(24); 5959–65. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · cited 2×
“They are recognized to bind to cereblon and induce degradation of transcriptional factors Ikaros and Aiolos (23).”
BackgroundLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“IMiDs, such as thalidomide, lenalidomide, and pomalidomide, exert significant activity in the treatment of multiple myeloma (2, 21, 22).”
BackgroundDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“Treatment was well tolerated in the daratumumab group, with adverse events consistent with the known profiles of the drugs in the combination (53).”
ResultSelf-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · cited 1×
“This benefit maintained regardless of patient age, number of prior lines of therapies, previous exposure to lenalidomide, or the presence of high-risk cytogenetics (44).”
BackgroundSelf-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001 · cited 1×
“Preliminary results of several phase I studies (35, 36) exploring the use of checkpoint inhibitors as single agents were disappointing, with no objective responses in patients with multiple myeloma, confirming the need for combinatory studies to antagonize additional inhibitory signals (37).”
BackgroundEvolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862 · cited 1×
“CD38 is an attractive target for immunotherapy treatment due to its high and uniform expression on multiple myeloma cells (49) and relatively low expression on normal lymphoid and myeloid cells and in some nonhematopoietic cells (50).”
BackgroundLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citationNK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Cited by
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationPhase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013
Ribrag, V., Avigan, D. E., Green, D. J., Wise‐Draper, T., Posada, J. G., Vij, R., Zhu, Y., Farooqui, M. Z. H., Marinello, P., & Siegel, D. S. (2019) · British Journal of Haematology · doi:10.1111/bjh.15888 · Cited by 82
Mateos, M., Orlowski, R. Z., Ocio, E. M., Rodríguez‐Otero, P., Reece, D., Moreau, P., Munshi, N., Avigan, D. E., Siegel, D. S., Ghori, R., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15946 · Cited by 73
“…study Multiple myeloma (MM) is characterised by generalised immune suppression, partly mediated by loss of T-cell repertoire, inhibition of antigen-presenting cells and increased expression of the inhibitory programmed death 1 (PD-1, also termed PDCD1) immune checkpoint pathway, (Neri et al, 2016).”
Background
Metadata
- Authors
- Neri, P., Bahlis, N. J., & Lonial, S.
- Venue
- Clinical Cancer Research
- Published
- 2016-12-15
- Volume
- 22
- Issue
- 24
- Pages
- 5959-5965
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2532841680
- Cited by
- 48
- References
- 18
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0184
- The paper
- Neri, P., Bahlis, N. J., & Lonial, S. (2016). New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.